Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $6.4 million.

  • Serina Therapeutics' Cash from Financing Activities rose 739302.33% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 16887.86%. This contributed to the annual value of $13.2 million for FY2024, which is 3124.07% up from last year.
  • Per Serina Therapeutics' latest filing, its Cash from Financing Activities stood at $6.4 million for Q3 2025, which was up 739302.33% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Cash from Financing Activities registered a high of $10.1 million during Q1 2023, and its lowest value of -$13000.0 during Q4 2023.
  • Over the past 5 years, Serina Therapeutics' median Cash from Financing Activities value was $2.0 million (recorded in 2021), while the average stood at $2.8 million.
  • In the last 5 years, Serina Therapeutics' Cash from Financing Activities tumbled by 10086.67% in 2023 and then soared by 4889090.91% in 2024.
  • Serina Therapeutics' Cash from Financing Activities (Quarter) stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then plummeted by 100.87% to -$13000.0 in 2023, then soared by 38800.0% to $5.0 million in 2024, then grew by 28.09% to $6.4 million in 2025.
  • Its Cash from Financing Activities stands at $6.4 million for Q3 2025, versus $5.6 million for Q2 2025 and $4.9 million for Q1 2025.